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Abstract
Background: Cytokines have been found to be the important mediators during renal graft outcome. Therefore, we
designed this study to investigate the role of recipients’ IL-1 β promoter (−511) and IL-1 β exon-5 (+3954)
polymorphisms with the risk of graft outcome.
Methodology: We enrolled one hundred recipients of living-related renal transplants together with the age and sex
matched controls from the healthy population not having any renal abnormality for this study. Genotype frequencies
of the IL-1 β promoter (−511) and IL-1 β exon-5 (+3954) were analyzed using PCR-RFLP technique.
Results: Our results revealed significant differences in the healthy control group and patient group in IL 1β +3954
(p < 0.001). The frequency of variant type TT genotype was higher in RE group as compared to SGF and showed 4 fold
risk of rejection (OR = 4.54, p < 0.069) although p value was not significant. The frequency of wild type CC genotype
and CT was not significant (p value 0.89 and 0.74 respectively).
Conclusion: Our findings suggest that there is a prevalence of mutated allele of IL-1 gene cluster in our population,
which may be responsible for renal dysfunction.
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Background
Renal Transplantation is the treatment of choice for end
stage renal disease (ESRD). However, acute rejection
(AR) remains important clinical problems accounting for
chronic allograft loss and suboptimal long-term outcome
[1, 2]. There is growing evidence of the genetic associ-
ation between certain cytokine or its receptor antagonist
and AR after renal transplantation. Interleukin-1 (IL-1)
plays a key role in inflammatory and immune-mediated
diseases. During allograft rejection, IL-1 production pre-
cedes allograft dysfunction and injury. The IL-1 system
is unique in having a natural inhibitor known as the IL-1
receptor antagonist (IL-1Ra) molecule [3]. Genes for IL-
1a, IL1β and IL-1Ra are located on chromosome 2q14–
21 [4]. Net effect of the three members of the IL-1 gene
family is to control inflammatory and host defense
responses as IL-1 causes vaso-relaxation, increases ad-
herence of lymphocytes and neutrophils to endothelial
cells and might be implicated in the immune-biology of
both acute and chronic graft rejection [5]. Some studies
[6–8] investigated the association of IL1β, IL-1 receptor
antagonist (IL-1ra) gene polymorphism with acute renal
graft rejection. However, the effects of these polymor-
phisms on AR after renal transplantation are still contro-
versial. It has been suggested that cytokine genotyping
may play a predictive role in identifying individuals who
are at higher risk of acute rejection by individualizing
their immunosuppression levels [9]. We sought to ascer-
tain whether polymorphisms of the gene encoding
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recipients IL-1β impacts on the incidence of acute renal
graft rejection.
Our aim of study was to identify non-HLA risk factors,
which may be used in pre-transplant patient assessment.
Our study investigated association of IL-1 β promoter
(−511) and IL-1 β exon-5 (+3954) genotypes with the
risk of graft outcome. Renal transplant patients were
analyzed for haplotype variation for evaluate its impact
in graft outcome including rejection episode (RE) and
stable graft function (SGF).
Methods
Our study was a hospital based retrospective study
that was carried out in the Departments of Internal
Medicine, Nephrology and Immunology & Molecular
Medicine, Sher-i-Kashmir Institute of Medical Sciences,
Srinagar. Renal allograft recipients were taken in the study
after informed consent and the study was ethically ap-
proved by Institutional Ethics Committee under ethical
clearance no. SIMS1 131/IEC-SKIMS/2014-25 dated 30th
April 2013.
Study population
Kidney Transplant recipients fulfilling the inclusion/
exclusion criteria admitted in the Department of
Nephrology and following Nephrology Out-Patient
Department were included in this study. One hundred
recipients of living-related renal transplants were en-
rolled in this study. Age and Sex matched controls
were selected from the healthy population not having
any renal abnormality.
Inclusion criteria
All the patients receiving Renal Allograft were taken for
the study. All were live both related and unrelated with
ABO compatible with maximum of 3/6 mismatch.
Exclusion criteria
Patients with other reasons (other than immunological
cause) for transplant rejection or failure like Technical
Problems, Graft failure due to any drug(like NSAIDS,
herbal medications and other nephrotoxic drugs),or dye
intake, uro-obstruction, infection, surgical failure, recur-
rence of original disease in transplanted kidney, Cyclos-
porine(CsA)/Tacrolimus toxicity etc. Patient who died
with a functioning graft during the study period was not
included in the study.
All patients received an immunosuppressive regimen
consisting of steroids, Tacrolimus and mycophenolate
mofetil. The steroid regimen consisted of intraven-
ously administered methylprednisolone 500 mg at the
time of surgery followed by intravenously adminis-
tered methylprednisolone 1 g/d for the next 3 days,
at which time the medication regimen was changed
to oral prednisolone 30 mg/d, which was progressively
tapered to 15 to 20 mg/d by the end of the first post-
surgical month. An increase in the serum creatinine
level that was > = 10% from the baseline value and
that could not be attributed to a cause such as urin-
ary flow obstruction, a toxic reaction to cyclosporine,
or a urinary tract infection was defined as clinical re-
jection. Episodes of acute clinical rejection were re-
corded and treated with steroid pulse therapy. If the
patient had no clinical response to that treatment, a
kidney biopsy was performed. Biopsy specimens were
graded according to the 2009 Banff criteria.
Methodology
 Peripheral blood of the patient was collected in 5 ml
EDTA vial after transplantation and was stored at
−80 °C till further use.
 DNA extraction was done by Phenol/Chloroform
method or DNA extraction kit.
 Polymerase Chain Reaction Amplification of the
desired region was done using specific primers and
followed by Restriction Fragment Length Polymorphism
method by Enzyme digestion method.
 Digestion products were checked on 3% Agarose gel
by electrophoresis.
 Patients were followed for detection of rejection of
graft function or graft dysfunction for minimum
1 year [See Fig. 1 for details].
Statistical analysis
Data was analyzed with the help of percentage statistics.
Allele and genotype frequencies were compared through
a 2x2 contingency table using chi-square test or Fischer’s
exact test, whichever appropriate. Odds ratio (OR) with
95% confidence interval (CI) was determined for the dis-
ease susceptibility of patients. Logistic regression ana-
lysis was performed to investigate the impact of other
prognostic factors like age, gender with graft outcome.
Statistical analysis was performed with help of SPSS soft-
ware version 16. P-values less than 0.05 were considered
statistically significant.
Results
Association of subject characteristics
Allograft function association with characteristics like
age and gender was seen by logistic regression studies
which showed no significant association as shown in
Table 1.
IL 1 genotypes and outcome of allograft function
Genotype frequency distributions for IL 1β exon-
5(+3954) among renal transplant patients are shown in
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Table 2. The frequency distribution was in Hardy-
Weinberg equilibrium. The results revealed significant
differences in the healthy control group and patient
group in IL 1β +3954 (p < 0.001). The frequency of C/C
was higher in patients as compared to controls (41.8 vs
16%). No significant difference was observed between
RE and SGF. The frequency of T/T genotype was higher
in RE group as compared to SGF and showed 4 fold risk
of rejection (OR = 4.54, p < 0.069) although p value was
not significant. The frequency of C/C genotype and C/T
was not significant (p value 0.89 and 0.74 respectively).
Genotype frequency distributions for IL 1β promoter
(−511) among renal transplant patients are shown in
Table 3. The results revealed significant differences be-
tween the healthy control and the patient groups in IL-
1β promoter region − 511 (p < 0.001). The frequency of
E1/E1 genotype was higher in patients as compared to
controls (45.1 vs.29%) and showed more than 2 folds in-
creased risk in patients(OR = 2.01). The frequency of
E1/E1 was also higher in RE group as compared to
SGF (60 vs. 36.1%) and showed 2.6 fold risk for RE
(OR = 2.66, p = 0.03)
Distribution of haplotypes and linkage disequilibrium
Haplotype frequencies among the two IL-1 gene poly-
morphisms in patients and controls and RE and SGF
are shown in Table 4. There was a significant differ-
ence in haplotype C-E1 frequency distribution among
patients and controls (OR = 1.557 p value = 0.016). All
the four haplotypes were present in rejection episodes
and stable graft function. There was non-significant
difference between Rejection episodes and stable graft
function.
Discussion
Despite advances in immunosuppressive therapy,
acute rejection remains an important cause of trans-
plant injury. For the past decade, the influence of
cytokine gene polymorphisms has been studied in pa-
tients with autoimmune disorders and those who have





Fig. 1 a Representative PCR amplification picture of IL-1B -51 T/C.
Lanes 1–7: 304 bp amplified PCR product of IL-1β -51 T/C, Lane M:
50 bp DNA Marker. b RFLP picture of IL-1β after restriction digestion
with Ava1 1 (3%) agarose gel electrophoresis. Lane M: 50 bp marker,
Lane 1, 2, 7, 9, And 11: homozygous wild TT genotype, Lane 4, 5, 6,
8: heterozygous TC genotype, Lane 3,10,12 : Homozygous variant CC
genotype. c Representative PCR amplification picture of IL-1β +3954.
Lanes 1–6:249 bp amplified PCR product of IL-1β + 3954, Lane M:
50 bp DNA Marker. d RFLP picture of IL-1β after restriction digestion
with Taq 1 (3%) agarose gel electrophoresis. Lane M: 50 bp marker,
Lane 1,3,4,5,6,8,10,11: homozygous wild CC genotype, Lane 2,7,9:
heterozygous TC genotype
Table 1 Association of subject characteristics
Characteristic SGF (n = 61) Rejection Episodes (n = 30)
Age (Yrs) 16–63 18–60
Sex
Male 46 (75.4%) 25 (83.3%)
Female 15 (24.6%) 5 (16.7%)
Donor Age
< 50 47 (77.1%) 24 (80%)




aothers include Hypertension¸Type 2 DM, Vasculitis, RPGN rapidly
proliferative glomerulonephritis
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results of those investigations are inconsistent. IL-1
plays a key role in inflammatory and immune-mediated
diseases. During allograft rejection, IL-1 production
precedes allograft dysfunction and injury. Marked inter-
individual and intra-individual variations in the produc-
tion of IL-1β, IL-10 TNF-α, IL-2, IL-4, IFN-γ, and other
cytokines have been reported, but attempts to define
the effects of particular genotypes on cytokine pro-
duction, both in vitro and in vivo, have produced in-
consistent results.
In our study a total of 91 patients of allograft renal
transplant were taken who have undergone transplant
after proper immunologic evaluation including cytotoxic
cross matching, HLA typing and ABO typing. 30 pa-
tients that constitute 32% developed rejection episodes
over a period of 2 years. 24(80%) patients out of these
rejection episodes responded to steroids, while as 6(20%)
patients were steroid resistant.
IL1β 511(C/T) polymorphism has been studied in vari-
ous studies regarding allograft function. We found sig-
nificant difference in the genotypic distribution of IL-1
gene cluster among patients and controls. The IL 1β
(+3954) CC genotype was observed more frequently in
the patients (41.8%) than the controls (16%) (OR = 3.76).
The IL 1β (−511) TT genotype was observed more fre-
quently in the patients (45.1%) than the controls (29%)
(OR = 2.01). These results were consistent with the stud-
ies of various other studies [6, 7, 10, 11]. This suggests
that there is prevalence of mutated allele of IL-1 gene
cluster in our population, which is responsible for allo-
graft rejection.
Manchanda et al., studied polymorphism in relation
with rejection episodes and stable graft function. They
observed that there was a non-Significant association be-
tween IL-1 (promoter region −511) and chronic rejec-
tion among kidney recipients, which was consistent with
the results of Uboldi de Capei et al [11, 12]. Seyhun et
al. observed no significant association of IL 1β poly-
morphism with rejection episodes as was seen by Jie
Zhao et al. in 2013 in Chinese population [13]. We ob-
served T/T genotype of IL 1β promoter −511 had >2.6
risk of rejection (OR = 2.66 p =0.031) which was signifi-
cant and consistent with results of Manchanda. It may
be due to the fact that allele 2 of IL1-511 (E1) is as-
sumed to represent a “high secretor” phenotype leading
to increased pro-inflammatory activity in autoimmune
and infectious diseases [14]. The frequency distribution
of IL 1β exon (+3954) varied among rejection episodes
Table 2 IL 1β +3954 T/C genotypes frequencies in transplant recipients as a whole and grouped and controls
Genotypes CC (%) CT (%) TT (%) No. Of Alleles C/T
Patients (n = 91) 38 (41.8%) 47 (51.6%) 06 (6.6%) 123/59 (67.6/32.4)
Controls (n = 200) 32 (16%) 110 (55%) 58 (29%) 174/226 (43.5/56.5)
OR at 95% CI 3.76 (2.144–6.608) 0.874 (0.532–1.436) 0.173 (0.071–0.418) 2.71 (1.874–3.913)
RE (n = 30) 12 (40%) 14 (46.7%) 4 (13.3%) 36/22 (62.1/37.9)
SGF (n = 61) 26 (42.6%) 33 (54.1%) 2 (3.3%) 85/37 (69.7/30.3)
P – value and OR at
95% CI (RE vs SGF)
0.811; OR = 0.89
(0.369–2.185)
0.505; OR = 0.74
(0.309–1.784)
0.069; OR = 4.54
(0.781–26.36)
0.309; OR = 0.71
(0.369–1.373)
Steroid responsive
RE (n = 24)
9 (37.5%) 11 (45.83%) 4 (16.66%) 29/19
(60.4/39.6)
Steroid Resistant
RE (n = 6)
3 (50%) 3 (50%) 0 9/3 (75/25)
Table 3 Genotype and allele frequencies of IL 1β -511 in transplant recipients as a whole and grouped and controls
Genotypes E1/E1 (%) E1/E2 (%) E2/E2 (%) No. Of Alleles C/T
Patients (n = 91) 41 (45.1%) 45 (49.4%) 5 (5.5%) 55/127 (30.2/69.8)
Controls (n = 200) 58 (29%) 110 (55%) 32 (16%) 174/226 (43.5/56.5)
OR at 95% CI 2.01 (1.201–3.356) 0.800 (0.487–1.315) 0.305 (0.115–0.812) 0.563 (0.387–0.817)
RE (n = 30) 18 (60%) 11 (36.7%) 01 (3.3%) 13/47 (21.7/78.3)
SGF (n = 61) 22 (36.1%) 35 (57.4%) 4 (6.5%) 43/79 (35.2/64.8)
P – value and OR at
95% CI (RE vs SGF)
0.031; OR = 2.66
(1.083–6.530)
0.063; OR = 0.43
(0.175–1.057)
0.885; OR = 0.491
(0.052–4.602)
0.062; OR = 0.508
(0.248–1.042)
Steroid responsive
RE (n = 24)
16 (66.6%) 8 (33.33%) 0 40/8 (83.3/16.6)
Steroid Resistant
RE (n = 6)
3 (50%) 2 (33.33%) 1 (16.66) 8/4 (66.66/33.3)
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and stable graft function. The T/T genotype showed 4
fold risk of rejection although it had low statistical
power (OR = 4.54 p = 0.069). Our results were consistent
with Manchanda who showed 2 fold risk of rejection. It
has been previously reported that presence of genotype
T/T of IL-1 exon-5 + 3954 increases pro-inflammatory
activity of IL-1 [15]. Thus, overproduction of IL-1 during
kidney transplant rejection may promote allograft dys-
function and injury.
Earlier studies suggested the importance of IL-1
haplotype reflecting differential regulation of IL-1Ra
expression by IL-1β and coordinated effects of poly-
morphisms that regulate IL-1 bioactivity in vivo [16].
Manchanda observed that there was significant differ-
ence IL-1β promoter, exon-5 haplotype distribution
between RE and SGF. We constructed haplotypes for
IL 1β polymorphism in our study. There was a sig-
nificant difference in haplotype C-E1 frequency distri-
bution among patients and controls (OR = 1.557 p value =
0.016). IL 1β gene (promoter −511 and exon +3954)
haplotype frequencies were comparable in RE, SGF. Be-
fore embarking on large-scale haplotype-based studies on
samples from genetically distinct populations, it is import-
ant to consider variation both in linkage disequilibrium
(LD) and in haplotype frequencies within and across
populations, as both vary considerably. Previous func-
tional studies suggest that the combination of alleles
may be an important aspect in the regulation of IL-1
gene expression [17].
Conclusion
Our study suggests that there is prevalence of mutated
allele of IL-1 gene cluster in our population, which may
be responsible for allograft rejection.
Abbrevations
AR: Acute rejection; CsA: Cyclosporine; ESRD: End stage renal disease; IL1
Ra: Interleukin 1 receptor antagonist; IL1: Interleukin 1; RE: Rejection episode;
SGF: Stable graft function; β: beta
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